Chemed (CHE) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Chemed (NYSE: CHE) in the last few weeks:

• 9/25/2026 – Chemed is now covered by UBS Group AG. They set a “buy” rating and a $650.00 price target on the stock.
• 9/25/2026 – Chemed is now covered by UBS Group AG. They set a “buy” rating and a $650.00 price target on the stock.
• 9/25/2026 – Chemed was upgraded by UBS Group AG to “strong-buy”.
• 9/19/2026 – Chemed was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/1/2026 – Chemed was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 7/31/2026 – Chemed had its price target raised by Oppenheimer Holdings, Inc. from $500.00 to $590.00. They now have an “outperform” rating on the stock.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were issued a $0.70 dividend. The ex-dividend date was Monday, August 17th. This represents a $2.80 dividend on an annualized basis and a yield of 0.5%. This is an increase from Chemed’s previous quarterly dividend of $0.60. Chemed’s dividend payout ratio (DPR) is presently 14.06%.

Insider Buying and Selling at Chemed

In other news, EVP Spencer Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the sale, the executive vice president owned 13,912 shares of the company’s stock, valued at approximately $7,526,948.48. This trade represents a 6.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Patrick Grace sold 190 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the completion of the sale, the director directly owned 3,533 shares of the company’s stock, valued at $1,879,556. The trade was a 5.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 7,190 shares of company stock valued at $3,806,260 in the last ninety days. Insiders own 3.33% of the company’s stock.

Chemed Corporation is a diversified holding company that operates businesses in the healthcare and residential and commercial services industries. Its primary operations are conducted through VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services are delivered in patients’ homes, hospice residences, nursing facilities, hospitals and other care settings, primarily throughout the United States. Care is provided by interdisciplinary teams that may include physicians, nurses, hospice aides, social workers and chaplains.

Roto-Rooter provides plumbing and drain-cleaning services, as well as water cleanup and related services for residential and commercial customers.